Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice

International Journal of Neuropsychopharmacology

Volumn 16, Issue 5, 2013, Pages 1021-1031

  Van Enkhuizen, Jordy ^a,b   Geyer, Mark A ^a,c   Kooistra, Klaas ^a,b   Young, Jared W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Bipolar mania; chronic treatment; dopamine transporter; mice; valproate

Indexed keywords

VALPROIC ACID; VANOXERINE;

ANIMAL CELL; ARTICLE; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MANIA; MOUSE; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; EXPLORATORY BEHAVIOR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERAZINES; TIME FACTORS; VALPROIC ACID;

EID: 84878001346     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001198     Document Type: Article

References (51)

1. Anand A, Barkay G, Dzemidzic M, Albrecht D, et al. (2011). Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 13:406-413.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
3. Bowden CL, Brugger AM, Swann AC, Calabrese JR, et al. (1994). Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J Am Med Assoc 271:918-924.
4. Chiu CT, Liu G, Leeds P, Chuang DM (2011). Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36:2406-2421.
5. Cipriani A, Barbui C, Salanti G, Rendell J, et al. (2011). Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306-1315.
6. d'Aquila PS, Panin F, Serra G (2006). Chronic valproate fails to prevent imipramine-induced behavioural sensitization to the dopamine D2-like receptor agonist quinpirole. Eur J Pharmacol 535:208-211.
7. Dencker D, Husum H (2010). Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 207:78-83.
8. Douma TN, Kolarz A, Postma Y, Olivier B, et al. (2011). The amphetamine-chlordiazepoxide mixture, a pharmacological screen for mood stabilizers, does not enhance amphetamine-induced disruption of prepulse inhibition. Behav Brain Res 225:377-381.
9. Du J, Creson TK, Wu LJ, Ren M, et al. (2008). The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosc 28:68-79.
10. Einat H, Yuan P, Gould TD, Li J, et al. (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23:7311-7316.
11. Flaisher-Grinberg S, Einat H (2010). Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine. Front Psychiatry 1:10.
12. Geyer MA, Russo PV, Masten VL (1986). Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25:277-288.
13. Gould TD, Einat H (2007). Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 31:825-831.
14. Greenwood TA, Schork NJ, Eskin E, Kelsoe JR (2006). Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11:125-133.
15. Grunze H, Vieta E, Goodwin GM, Bowden C, et al. (2009). The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders : update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:85-116.
16. Guidotti A, Auta J, Chen Y, Davis JM, et al. (2011). Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60:1007-1016.
17. Harrison-Read PE (2009). Models of mania and antimanic drug actions: progressing the endophenotype approach. J Psychopharmacol 23:334-337.
18. Henry BL, Minassian A, van Rhenen M, Young JW, et al. (2011). Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology 215:697-707.
19. Herzog CJ, Miot S, Mansuy IM, Giros B, et al. (2008). Chronic valproate normalizes behavior in mice overexpressing calcineurin. Eur J Pharmacol 580:153-160.
20. Horschitz S, Hummerich R, Lau T, Rietschel M, et al. (2005). A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression. Mol Psychiatry 10:1104-1109.
21. Kalinichev M, Dawson LA (2011). Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 14:1051-1067.
22. Kim WY, Kim S, Kim JH (2008). Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity. Neurosci Lett 432:54-57.
23. Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, et al. (2007). Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 129:8328-8332.
24. Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, et al. (2008). Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 147B:134-166.
25. Loos M, Staal J, Schoffelmeer AN, Smit AB, et al. (2010). Inhibitory control and response latency differences between C57BL/6J and DBA/2J mice in a Go/No-Go and 5-choice serial reaction time task and strain-specific responsivity to amphetamine. Behav Brain Res 214:216-224.
26. Merikangas KR, Jin R, He JP, Kessler RC, et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241-251.
27. Minassian A, Henry BL, Young JW, Masten V, et al. (2011). Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. Public Libr Sci One 6:e24185.
28. Paulus MP, Dulawa SC, Ralph RJ, Geyer MA (1999). Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. Brain Res 835:27-36.
29. Paulus MP, Geyer MA (1991). A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology (Berlin) 104:6-16.
30. Peeler DF, Nowakowski RS (1987). Genetic factors and the measurement of exploratory activity. Behav Neural Biol 48:90-103.
31. Perry W, Minassian A, Paulus MP, Young JW, et al. (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66:1072-1080.
32. Pinsonneault JK, Han DD, Burdick KE, Kataki M, et al. (2011). Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36:1644-1655.
33. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, et al. (2003). Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 53:352-359.
34. Ramadan E, Basselin M, Taha AY, Cheon Y, et al. (2011). Chronic valproate treatment blocks D(2)-like receptor-mediated brain signaling via arachidonic acid in rats. Neuropharmacology 61:1256-1264.
35. Rapoport SI, Basselin M, Kim HW, Rao JS (2009). Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61:185-209.
36. Risbrough VB, Masten VL, Caldwell S, Paulus MP, et al. (2006). Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31:2349-2358.
37. Shaldubina A, Einat H, Szechtman H, Shimon H, et al. (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109:433-440.
38. Sutton LP, Rushlow WJ (2011). The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience 199:116-124.
39. Sylvia LG, Alloy LB, Hafner JA, Gauger MC, et al. (2009). Life events and social rhythms in bipolar spectrum disorders: a prospective study. Behav Ther 40:131-141.
40. van Enkhuizen J, Geyer MA, Kooistra K, Young JW (2012). Differential effects of dopamine transporter inhibitors in the rodent Iowa Gambling Task: relevance to mania. Psychopharmacology. Published online: 4 September 2012. doi:10.1007/s00213-012-2854-2.
41. Abstract. Wang J, Michelhaugh SK, Bannon MJ (2007). Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur J Neurosci 25:1982-1986.
42. Wingo AP, Ghaemi SN (2008). Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull 41:37-47.
43. Yatham LN, Torres IJ, Malhi GS, Frangou S, et al. (2010). The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC). Bipolar Disord 12:351-363.
44. Young JW, Geyer MA (2010). Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry 67:784-787.
45. Young JW, Goey AK, Minassian A, Perry W, et al. (2010a). GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology 208:443-454.
46. Young JW, Goey AK, Minassian A, Perry W, et al. (2010b). The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 96:7-15.
47. Young JW, Henry BL, Geyer MA (2011a). Predictive animal models of mania, hits, misses, and future directions. Br J Pharmacol 164:1263-1284.
48. Young JW, Kooistra K, Geyer MA (2011b). Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology 36:1385-1396.
49. Young JW, Minassian A, Paulus MP, Geyer MA, et al. (2007). A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31:882-896.
50. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA (2011c). Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol 25:934-943.
51. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, et al. (2001). Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 98:1982-1987.